866-897-8297

Call Is Confidential & Toll Free

Jakafi

Jakafi is a janus-associated kinase inhibitor indicated to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis. FDA approved on November 16, 2011.

The mean half-maximal inhibitory concentration (IC50) for JAK 1 and JAK 2 are 2.8 nmol/L and 3.3 nmol/L respectively. After administration of jakafi, a decrease in levels of phosphorylated STAT (marker for JAK activity) in a dose-dependent manner can be observed. Pharmacodynamic resistance has not been observed.

Thrombocytopenia was the dose-limiting toxicity.

Imprints


Drug: Jakafi
Strength: 15 Mg
Pill Imprint: INCY 15
Color: White
Shape: Elliptical / Oval

View Images & Details

Drug: Jakafi
Strength: 10 Mg
Pill Imprint: INCY 10
Color: White
Shape: Round

View Images & Details

Drug: Jakafi
Strength: 20 Mg
Pill Imprint: INCY 20
Color: White
Shape: Capsule-shape

View Images & Details

Drug: Jakafi
Strength: 5 Mg
Pill Imprint: INCY 5
Color: White
Shape: Round

View Images & Details

Drug: Jakafi
Strength: 25 Mg
Pill Imprint: INCY 25
Color: White
Shape: Elliptical / Oval

View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?